Autolus Therapeutics (AUTL) Consolidated Net Income (2017 - 2025)
Historic Consolidated Net Income for Autolus Therapeutics (AUTL) over the last 9 years, with Q3 2025 value amounting to -$79.1 million.
- Autolus Therapeutics' Consolidated Net Income rose 362.51% to -$79.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$224.8 million, marking a year-over-year increase of 1680.99%. This contributed to the annual value of -$220.7 million for FY2024, which is 589.25% down from last year.
- Autolus Therapeutics' Consolidated Net Income amounted to -$79.1 million in Q3 2025, which was up 362.51% from -$47.9 million recorded in Q2 2025.
- Autolus Therapeutics' 5-year Consolidated Net Income high stood at -$6.8 million for Q4 2021, and its period low was -$44.8 billion during Q3 2021.
- Over the past 5 years, Autolus Therapeutics' median Consolidated Net Income value was -$45.8 million (recorded in 2023), while the average stood at -$2.4 billion.
- In the last 5 years, Autolus Therapeutics' Consolidated Net Income crashed by 8428307.1% in 2021 and then skyrocketed by 9990.45% in 2022.
- Over the past 5 years, Autolus Therapeutics' Consolidated Net Income (Quarter) stood at -$6.8 million in 2021, then crashed by 298.16% to -$27.0 million in 2022, then plummeted by 186.04% to -$77.2 million in 2023, then skyrocketed by 64.23% to -$27.6 million in 2024, then plummeted by 186.6% to -$79.1 million in 2025.
- Its last three reported values are -$79.1 million in Q3 2025, -$47.9 million for Q2 2025, and -$70.2 million during Q1 2025.